World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.
about
Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutantsNatural History and Clinical Consequences of Hepatitis B Virus InfectionEpidemiology and Prevention of Hepatitis B Virus InfectionKASL clinical practice guidelines: management of chronic hepatitis BGenetic variation of hepatitis B virus and its significance for pathogenesisMutation profiling of the hepatitis B virus strains circulating in North Indian populationAnalysis of minimum target prices for production of entecavir to treat hepatitis B in high- and low-income countriesCurrent role of transient elastography in the management of chronic hepatitis B patientsA new model mimicking persistent HBV e antigen-negative infection using covalently closed circular DNA in immunocompetent mice.Development of a molecular-beacon assay to detect the G1896A precore mutation in hepatitis B virus-infected individuals.Prevalence and Characteristics of Precore Mutation in Iran and Its Correlation with Genotypes of Hepatitis B.HBeAg negative variants and their role in the natural history of chronic hepatitis B virus infection.Clinical implications of hepatitis B virus mutations: recent advances.Mutations in pre-core and basal-core promoter regions of hepatitis B virus in chronic HBV patients from Golestan, Iran.Association of core promoter mutations of hepatitis B virus and viral load is different in HBeAg(+) and HBeAg(-) patients.Prevalence of hepatitis B virus precore stop codon mutations in chronically infected childrenMolecular analysis of hepatitis B virus isolates in Mexico: predominant circulation of hepatitis B virus genotype H.Clinical profile of hepatitis B virus chronic infection in patients of Brazilian liver reference units.Natural history of chronic hepatitis B: phases in a complex relationship.A case-control study on sequence variations in the enhancer II/core promoter/precore and X genes of hepatitis B virus in patients with hepatocellular carcinoma.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates.Seroprevalence of hepatitis B e antigen (HBe antigen) and B core antibodies (IgG anti-HBcore and IgM anti-HBcore) among hepatitis B surface antigen positive blood donors at a Tertiary Centre in Nigeria.Viral blips during long-term treatment with standard or double dose lamivudine in HBe antigen negative chronic hepatitis BEffect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: systematic review and meta-analysis.Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B.Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progressionCombination treatment in HBeAg-negative chronic hepatitis B.Hepatitis B: epidemiological, immunological, and serological considerations emphasizing mutation.Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection.Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections.Characteristics of adults in the hepatitis B research network in North America reflect their country of origin and hepatitis B virus genotype.Precore and core promoter mutations of the hepatitis B virus gene in chronic genotype C-infected children.Clinical update: hepatitis BLong-term outcomes after nucleos(t)ide analogues discontinuation in chronic hepatitis B patients with HBeAg-negativeHepatitis B e-antigen negative chronic hepatitis B.Expertise of laboratories in viral load quantification, genotyping, and precore mutant determination for hepatitis B virus in a multicenter study.High rate of core promoter and precore mutations in patients with chronic hepatitis B.Natural history of chronic hepatitis B virus infection based on laboratory testing.
P2860
Q24563991-4CFB3500-65EE-4EA5-A9E3-50005ACCD4B7Q24810151-8338E79C-DD92-4A42-88DD-62C7A5264DBFQ24810152-058852BA-02A1-4197-BEEF-86F10148EAC2Q26752475-89BE51F7-FC66-48EE-AD91-6615BF3A56A3Q26772348-9327313A-C057-4CD1-BE3C-2CB45845AD74Q28540948-F131CE62-61B3-4C46-B51E-01F2F53C4185Q28830093-98B027CB-8D6A-43DC-B3E4-699497A5CDFAQ30358894-18513809-F6E7-46A3-BA14-8EA0BE5F2CE8Q33585283-5BF4A4A8-6A37-4ADE-9B59-F25AB828311CQ33592384-FB296B32-B4D8-494B-A915-FFCA05555B6EQ33764123-27867836-C178-4F5D-9E39-C969D86391BFQ33801305-3BAF91AA-3EFB-4BA9-9EA8-0240069D78AAQ33801311-DF7B4B5D-2143-45DA-A29A-E1F3D02FA7E3Q33802585-C4C5AB0A-6CF2-43E3-B5EF-B813F794F60CQ33841903-3C8C6E29-9A48-46CB-8307-FE013F2309F5Q33867148-2A7478CD-9884-488D-9E3A-6C88046A1FF5Q33909717-84692768-F1D0-4426-8087-279363A25A85Q33977147-00106A95-7F7E-4569-97BD-65CDB9AA6FBEQ34036650-66CFC3A2-2C24-4A78-9133-89FB35FADAF5Q34130365-4784FB61-6C87-4EA3-840A-3F4C86D25911Q34137291-C48C3125-73B7-44AF-AC88-8F91D3946299Q34168465-288D6DF2-52D5-4466-B84E-77B4BFBD7E74Q34210772-3C03A0C4-92D3-4C26-898A-1D57E28E323EQ34233156-6BAD0D64-7B45-4442-8D23-4CF3ED0E0B1DQ34343621-B8D60527-FEBA-4609-B7FD-79F4A3A647DAQ34382099-90078EF3-605F-4212-BEDD-8BE3B5382066Q34384612-8274FD29-662B-4626-864B-7C47ABC488E6Q34391476-8041AD36-D6E8-4929-96E6-147F9638E21EQ34550746-9A897E2F-D777-43CD-BA3B-1D5AD4E90714Q34584406-6D968C46-DAD5-4B37-A194-28080F7D1DFFQ34606036-A839A268-1E2F-4680-B9AF-EDFC40264EA9Q34683065-F2F76BAF-2E72-42D2-AE33-C8D731E71476Q34716864-506C4321-7BBE-40FB-948A-BB6291940E90Q34753430-19D25322-9E12-4C31-819C-DA1C7FD12BEAQ34996687-8DDA90AE-3EA1-44D4-B11D-977ED698FF2DQ35007336-8B8A94B0-9CD1-4272-951C-B5B3056CEF88Q35020821-5A96983D-528B-4517-A31E-5E5882C5E7BFQ35073559-86960E5F-4C4A-4385-A297-2779ABE3B0DDQ35288857-40B725C0-95BA-4499-A429-36F2A3C7B728Q35457844-B8141082-A3BB-4D68-A201-0313F346E8D5
P2860
World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
World-wide epidemiology of HBe ...... re and core promoter variants.
@ast
World-wide epidemiology of HBe ...... re and core promoter variants.
@en
World-wide epidemiology of HBe ...... re and core promoter variants.
@nl
type
label
World-wide epidemiology of HBe ...... re and core promoter variants.
@ast
World-wide epidemiology of HBe ...... re and core promoter variants.
@en
World-wide epidemiology of HBe ...... re and core promoter variants.
@nl
prefLabel
World-wide epidemiology of HBe ...... re and core promoter variants.
@ast
World-wide epidemiology of HBe ...... re and core promoter variants.
@en
World-wide epidemiology of HBe ...... re and core promoter variants.
@nl
P2093
P2860
P1476
World-wide epidemiology of HBe ...... re and core promoter variants.
@en
P2093
P2860
P356
10.1046/J.1365-2893.2002.00304.X
P577
2002-01-01T00:00:00Z